European Urology - Current issue

European Urology - Current issue http://europeanurology.com European Urology RSS feed of the current issue. AIMS AND SCOPE Elsevier is the publisher of European Urology, the official journal of the European Association of Urology. European Urology publishes peer-reviewed original articles and topical reviews on a wide range of urological problems. Topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, as well as recent advances in techniques, instrumentation, surgery and pediatric urology provide readers with a complete guide to international developments in urology. Published monthly, European Urology is an important journal for all clinicians and researchers in this field. All members of the EAU receive the journal as a benefit of their membership. For more information on the European Association of Urology, please go to: http://www.uroweb.org Supplements to European Urology are published under the title European Urology Supplements (ISSN 1569-9056). All subscribers to European Urology automatically receive this publication. You can also visit the EAU-EBU Update Series (ISSN 1871-2592). en-US © 2013 Published by Elsevier Inc. All rights reserved. <![CDATA[Editorial Board]]> http://europeanurology.com/article/S0302-2838(13)00427-2/abstract Thu, 06 Jun 2013 05:55:06 GMT S0302-2838(13)00427-2 <![CDATA[Contents]]> http://europeanurology.com/article/S0302-2838(13)00430-2/abstract Thu, 06 Jun 2013 05:55:05 GMT S0302-2838(13)00430-2 <![CDATA[Award pages]]> http://europeanurology.com/article/S0302-2838(13)00428-4/abstract Thu, 06 Jun 2013 05:55:03 GMT S0302-2838(13)00428-4 <![CDATA[Re: Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Gurin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance]]> http://europeanurology.com/article/S0302-2838(13)00390-4/abstract Thu, 06 Jun 2013 05:25:10 GMT S0302-2838(13)00390-4 <![CDATA[Re: Long-term Endoscopic Management of Upper Tract Urothelial Carcinoma: 20-year Single-centre Experience]]> http://europeanurology.com/article/S0302-2838(13)00389-8/abstract Thu, 06 Jun 2013 05:25:09 GMT S0302-2838(13)00389-8 <![CDATA[Re: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing]]> http://europeanurology.com/article/S0302-2838(13)00388-6/abstract Thu, 06 Jun 2013 05:25:08 GMT S0302-2838(13)00388-6 <![CDATA[Re: Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-resistant Prostate Cancer Cell Lines]]> http://europeanurology.com/article/S0302-2838(13)00387-4/abstract Thu, 06 Jun 2013 05:25:05 GMT S0302-2838(13)00387-4 <![CDATA[Re: Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy]]> http://europeanurology.com/article/S0302-2838(13)00386-2/abstract Thu, 06 Jun 2013 05:25:03 GMT S0302-2838(13)00386-2 <![CDATA[Re: Dutasteride in Localised Prostate Cancer Management: The REDEEM Randomised, Double-Blind, Placebo-Controlled Trial]]> http://europeanurology.com/article/S0302-2838(13)00385-0/abstract Thu, 06 Jun 2013 05:25:01 GMT S0302-2838(13)00385-0 <![CDATA[Congress Calendar]]> http://europeanurology.com/article/S0302-2838(13)00460-0/abstract Thu, 06 Jun 2013 05:15:05 GMT S0302-2838(13)00460-0 <![CDATA[The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis]]> http://europeanurology.com/article/S0302-2838(13)00382-5/abstract Wed, 01 May 2013 11:25:03 GMT S0302-2838(13)00382-5 <![CDATA[Reply from Authors re: Brant A. Inman, Michael R. Abern. Interpreting a Study on Bladder Cancer Screening. Eur Urol 2013;64:4850]]> http://europeanurology.com/article/S0302-2838(13)00384-9/abstract Mon, 29 Apr 2013 14:35:23 GMT S0302-2838(13)00384-9 <![CDATA[Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's Letter to the Editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Foss, Kristin Austlid Taskn. Association Between Use of -Blockers and Prostate CancerSpecific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007]]> http://europeanurology.com/article/S0302-2838(13)00299-6/abstract Tue, 16 Apr 2013 12:15:01 GMT S0302-2838(13)00299-6 <![CDATA[Interpreting a Study on Bladder Cancer Screening]]> http://europeanurology.com/article/S0302-2838(13)00301-1/abstract Tue, 16 Apr 2013 11:35:06 GMT S0302-2838(13)00301-1 <![CDATA[Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)]]> http://europeanurology.com/article/S0302-2838(13)00294-7/abstract Tue, 16 Apr 2013 11:18:09 GMT S0302-2838(13)00294-7 <![CDATA[Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Foss, Kristin Austlid Taskn. Association Between Use of -Blockers and Prostate Cancerspecific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-risk or Metastatic Disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.]]> http://europeanurology.com/article/S0302-2838(13)00300-X/abstract Tue, 16 Apr 2013 11:15:01 GMT S0302-2838(13)00300-X <![CDATA[Reply to Kathleen DHauwers, Gunter De Win and Wiebren Tjalmas Letter to the Editor re: Katja Kero, Jaana Rautava, Kari Syrjnen, Seija Grenman, Stina Syrjnen. Oral Mucosa as a Reservoir of Human Papillomavirus: Point Prevalence, Genotype Distribution, and Incident Infections Among Males in a 7-year Prospective Study. Eur Urol 2012;62:106370]]> http://europeanurology.com/article/S0302-2838(13)00367-9/abstract Tue, 16 Apr 2013 10:43:17 GMT S0302-2838(13)00367-9 <![CDATA[Re: Katja Kero, Jaana Rautava, Kari Syrjnen, Seija Grenman, Stina Syrjnen. Oral Mucosa as a Reservoir of Human Papillomavirus: Point Prevalence, Genotype Distribution, and Incident Infections Among Males in a 7-year Prospective Study. Eur Urol 2012;62:106370]]> http://europeanurology.com/article/S0302-2838(13)00366-7/abstract Tue, 16 Apr 2013 10:43:13 GMT S0302-2838(13)00366-7 <![CDATA[Corrigendum to Intratunical Injection of Human Adipose Tissuederived Stem Cells Prevents Fibrosis and Is Associated with Improved Erectile Function in a Rat Model of Peyronie's Disease [Eur Urol 2013;63:55160]]]> http://europeanurology.com/article/S0302-2838(13)00368-0/abstract Tue, 16 Apr 2013 10:06:33 GMT S0302-2838(13)00368-0 <![CDATA[EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction]]> http://europeanurology.com/article/S0302-2838(13)00228-5/abstract 40 ml, profit from 5α-reductase inhibitors (5-ARIs) that slowly reduce LUTS and the probability of urinary retention or the need for surgery. Antimuscarinics might be considered for patients who have predominant bladder storage symptoms. The phosphodiesterase type 5 inhibitor tadalafil can quickly reduce LUTS to a similar extent as α1-blockers, and it also improves erectile dysfunction. Desmopressin can be used in men with nocturia due to nocturnal polyuria. Treatment with an α1-blocker and 5-ARI (in men with enlarged prostates) or antimuscarinics (with persistent storage symptoms) combines the positive effects of either drug class to achieve greater efficacy. Prostate surgery is indicated in men with absolute indications or drug treatment–resistant LUTS due to benign prostatic obstruction. Transurethral resection of the prostate (TURP) is the current standard operation for men with prostates 30–80 ml, whereas open surgery or transurethral holmium laser enucleation is appropriate for men with prostates >80 ml. Alternatives for monopolar TURP include bipolar TURP and transurethral incision of the prostate (for glands Non-neurogenic male lower urinary tract symptoms (LUTS) have multifactorial aetiology. Treatment ranges from watchful waiting to medical therapy to surgical treatment. The choice of treatment depends on findings assessed during evaluation; ability of the treatment to change assessed findings; treatment preferences of the individual patient; and expectations to be met in terms of speed of onset, efficacy, side effects, quality of life, and disease progression. These symptom-oriented guidelines are based on the best available evidence and provide practical guidance for the management of men experiencing LUTS.]]> Thu, 21 Mar 2013 15:45:01 GMT S0302-2838(13)00228-5 <![CDATA[Germline Homeobox B13 () G84E Mutation and Prostate Cancer Risk in European Descendants: A Meta-analysis of 24 213 Cases and 73 631 Controls]]> http://europeanurology.com/article/S0302-2838(13)00231-5/abstract Thu, 21 Mar 2013 14:55:01 GMT S0302-2838(13)00231-5 <![CDATA[Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers]]> http://europeanurology.com/article/S0302-2838(13)00219-4/abstract Mon, 11 Mar 2013 09:45:02 GMT S0302-2838(13)00219-4 <![CDATA[Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. Eur Urol 2013;64:589]]> http://europeanurology.com/article/S0302-2838(13)00171-1/abstract Mon, 11 Mar 2013 09:45:01 GMT S0302-2838(13)00171-1 <![CDATA[Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. Eur Urol 2013;64:379]]> http://europeanurology.com/article/S0302-2838(13)00140-1/abstract Mon, 11 Mar 2013 09:05:13 GMT S0302-2838(13)00140-1 <![CDATA[Reply from Authors re: Jean-Nicolas Cornu. Overactive Bladder Medical Management in the Elderly: It Is Time to Go Beyond the Tip of the Iceberg. Eur Urol 2013;64:823]]> http://europeanurology.com/article/S0302-2838(13)00141-3/abstract Mon, 11 Mar 2013 09:05:12 GMT S0302-2838(13)00141-3 <![CDATA[Corrigendum to EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence [Eur Urol 2012;62:113042]]]> http://europeanurology.com/article/S0302-2838(13)00170-X/abstract Mon, 11 Mar 2013 08:55:06 GMT S0302-2838(13)00170-X <![CDATA[Antiplatelet Therapy in Patients With Coronary Stent Undergoing Urologic Surgery: Is It Still No Man's Land?]]> http://europeanurology.com/article/S0302-2838(13)00095-X/abstract Mon, 18 Feb 2013 09:45:25 GMT S0302-2838(13)00095-X <![CDATA[Overactive Bladder Medical Management in the Elderly: It Is Time to Go Beyond the Tip of the Iceberg]]> http://europeanurology.com/article/S0302-2838(13)00101-2/abstract Thu, 07 Feb 2013 17:25:05 GMT S0302-2838(13)00101-2 <![CDATA[What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes]]> http://europeanurology.com/article/S0302-2838(13)00099-7/abstract Thu, 07 Feb 2013 17:25:01 GMT S0302-2838(13)00099-7 <![CDATA[Active Surveillance, Quality of Life, and Cancer-related Anxiety]]> http://europeanurology.com/article/S0302-2838(13)00092-4/abstract Thu, 07 Feb 2013 16:25:02 GMT S0302-2838(13)00092-4 <![CDATA[Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance]]> http://europeanurology.com/article/S0302-2838(13)00012-2/abstract Wed, 23 Jan 2013 14:15:11 GMT S0302-2838(13)00012-2 <![CDATA[ESUT Expert Group on Laparoscopy Proposes Uniform Terminology During Radical Prostatectomy: We Need to Speak the Same Language]]> http://europeanurology.com/article/S0302-2838(13)00026-2/abstract Wed, 23 Jan 2013 14:15:01 GMT S0302-2838(13)00026-2 <![CDATA[Randomised, Multicentre, Placebo-controlled, Double-blind Crossover Study Investigating the Effect of Solifenacin and Oxybutynin in Elderly People with Mild Cognitive Impairment: The SENIOR Study]]> http://europeanurology.com/article/S0302-2838(13)00005-5/abstract Thu, 17 Jan 2013 13:55:17 GMT S0302-2838(13)00005-5 <![CDATA[Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium]]> http://europeanurology.com/article/S0302-2838(13)00013-4/abstract Thu, 17 Jan 2013 13:45:01 GMT S0302-2838(13)00013-4 <![CDATA[Surgical Reconstruction for Male-to-Female Sex Reassignment]]> http://europeanurology.com/article/S0302-2838(12)01560-6/abstract Tue, 08 Jan 2013 10:35:01 GMT S0302-2838(12)01560-6 <![CDATA[Reply from Authors re: Brian R. Matlaga. How Do We Manage Infected, Obstructed Hydronephrosis? Eur Urol 2013;64:934]]> http://europeanurology.com/article/S0302-2838(12)01330-9/abstract Fri, 09 Nov 2012 03:35:02 GMT S0302-2838(12)01330-9 <![CDATA[Reply from Authors re: Martin Spahn, Steven Joniau. Positive Surgical Margin at Radical Prostatectomy: Futile or Surgeon-dependent Predictor of Prostate Cancer Death? Eur Urol 2013;64:268]]> http://europeanurology.com/article/S0302-2838(12)01323-1/abstract Tue, 06 Nov 2012 03:35:29 GMT S0302-2838(12)01323-1 <![CDATA[Reply from Authors re: Camillo Porta, Chiara Paglino. Experience Gathered from Retrospective Series on Renal Cell Carcinoma Is Useful, But Now It Is Time for a Global Claim for Academically Driven Prospective Studies. Eur Urol 2013;64:712]]> http://europeanurology.com/article/S0302-2838(12)01233-X/abstract Thu, 18 Oct 2012 02:36:01 GMT S0302-2838(12)01233-X <![CDATA[How Do We Manage Infected, Obstructed Hydronephrosis?]]> http://europeanurology.com/article/S0302-2838(12)01231-6/abstract Wed, 17 Oct 2012 02:35:37 GMT S0302-2838(12)01231-6 <![CDATA[Experience Gathered from Retrospective Series on Renal Cell Carcinoma Is Useful, But Now It Is Time for a Global Claim for Academically Driven Prospective Studies]]> http://europeanurology.com/article/S0302-2838(12)01116-5/abstract Thu, 27 Sep 2012 02:35:56 GMT S0302-2838(12)01116-5 <![CDATA[Temporal Trends, Practice Patterns, and Treatment Outcomes for Infected Upper Urinary Tract Stones in the United States]]> http://europeanurology.com/article/S0302-2838(12)01103-7/abstract Tue, 25 Sep 2012 02:48:32 GMT S0302-2838(12)01103-7 <![CDATA[Controlling Health Care Costs for Prostate Cancer]]> http://europeanurology.com/article/S0302-2838(12)01094-9/abstract Tue, 18 Sep 2012 02:46:02 GMT S0302-2838(12)01094-9 <![CDATA[Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell Carcinoma]]> http://europeanurology.com/article/S0302-2838(12)01027-5/abstract Wed, 12 Sep 2012 02:36:08 GMT S0302-2838(12)01027-5 <![CDATA[Positive Surgical Margin at Radical Prostatectomy: Futile or Surgeon-dependent Predictor of Prostate Cancer Death?]]> http://europeanurology.com/article/S0302-2838(12)01016-0/abstract Wed, 05 Sep 2012 02:35:57 GMT S0302-2838(12)01016-0 <![CDATA[Locally Recurrent Prostate Cancer Following Radiation Therapy: To Cut or To Freeze?]]> http://europeanurology.com/article/S0302-2838(12)00980-3/abstract Wed, 29 Aug 2012 02:45:02 GMT S0302-2838(12)00980-3 <![CDATA[Hospitalization Costs for Radical Prostatectomy Attributable to Robotic Surgery]]> http://europeanurology.com/article/S0302-2838(12)00947-5/abstract Tue, 21 Aug 2012 02:45:16 GMT S0302-2838(12)00947-5 <![CDATA[The Impact of Solitary and Multiple Positive Surgical Margins on Hard Clinical End Points in 1712 Adjuvant TreatmentNaive pT24 N0 Radical Prostatectomy Patients]]> http://europeanurology.com/article/S0302-2838(12)00926-8/abstract Fri, 10 Aug 2012 02:35:19 GMT S0302-2838(12)00926-8 <![CDATA[Salvage Cryosurgery of the Prostate for Failure After Primary Radiotherapy or Cryosurgery: Long-term Clinical, Functional, and Oncologic Outcomes in a Large Cohort at a Tertiary Referral Centre]]> http://europeanurology.com/article/S0302-2838(12)00813-5/abstract Fri, 20 Jul 2012 00:16:39 GMT S0302-2838(12)00813-5 <![CDATA[Does Comorbidity Influence the Risk of Myocardial Infarction or Diabetes During Androgen-Deprivation Therapy for Prostate Cancer?]]> http://europeanurology.com/article/S0302-2838(12)00501-5/abstract 0.10 for all interactions, with one exception). Previous MI, congestive heart failure, peripheral arterial disease, stroke, hypertension, chronic obstructive pulmonary disease, and renal disease were associated with new MI and diabetes, and obesity and rheumatologic disease were also associated with diabetes. Limitations include the observational study design, reliance on administrative data to ascertain outcomes, and lack of information on risk factors such as smoking and family history.Conclusions:Traditional risk factors for MI and diabetes were also associated with developing these conditions during ADT but did not significantly modify the risk attributable to ADT. Strategies to screen and prevent diabetes and cardiovascular disease in men with PCa should be similar to the strategies recommended for the general population.Traditional risk factors for myocardial infarction and diabetes are also associated with developing these conditions during androgen-deprivation therapy, but they do not appear to significantly modify the risk attributable to androgen-deprivation therapy. Strategies to screen for and prevent diabetes and cardiovascular disease in men with prostate cancer should be similar to strategies recommended for the general population.]]> Thu, 19 Apr 2012 02:45:05 GMT S0302-2838(12)00501-5